Clinical Trials Logo

Lymphoma, Mantle-cell clinical trials

View clinical trials related to Lymphoma, Mantle-cell.

Filter by:

NCT ID: NCT03601819 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders

Start date: May 15, 2019
Phase: Phase 1
Study type: Interventional

This trial will determine the safety and tolerability of Pacritinib in patients with relapsed/refractory lymphoproliferative disorders.

NCT ID: NCT03585725 Terminated - Clinical trials for Mantle Cell Lymphoma

A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma

Start date: September 26, 2018
Phase: Early Phase 1
Study type: Interventional

This is a A Pilot Investigator-Initiated Study of Ribavirin in Indolent Follicular Lymphoma and Mantle Cell Lymphoma

NCT ID: NCT03579888 Terminated - Clinical trials for Recurrent Mantle Cell Lymphoma

CD19-Specific T Cells Post AlloSCT

Start date: June 26, 2020
Phase: Phase 1
Study type: Interventional

This phase I trial investigates the side effects and best dose of CD19 positive (+) specific CAR-T cells in treating patients with CD19+ lymphoid malignancies, such as acute lymphoblastic leukemia, non-Hodgkin lymphoma, small lymphocytic lymphoma, or chronic lymphocytic lymphoma. Sometimes researchers change the genetic material in the cells of a patient's T cells using a process called gene transfer. Researchers then inject the changed T-cells into the patient's body. Receiving the T-cell infusion may help to control the disease.

NCT ID: NCT03571828 Terminated - Clinical trials for Follicular Lymphoma (FL)

Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma

Start date: October 29, 2018
Phase: Phase 1
Study type: Interventional

Evaluate the safety and tolerability of AMG 562 in adult subjects with DLBCL, MCL, or FL. Estimate the maximum tolerated dose (MTD) and/or a biologically active dose (e.g., recommended phase 2 dose [RP2D])

NCT ID: NCT03436771 Terminated - Multiple Myeloma Clinical Trials

Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell Product

Start date: February 19, 2018
Phase:
Study type: Observational

This study will provide long-term follow-up for patients who have received treatment with a Juno CAR T-cell product in a Juno-sponsored clinical trial. In this study, patients will be followed for up to 15 years after their last dose of Juno CAR T cells for evaluation of delayed adverse events, presence of persisting CAR T-cell vector sequences, presence of replication-competent retrovirus (RCR) or lentivirus (RCL), and survival.

NCT ID: NCT03311126 Terminated - Clinical trials for Mantle Cell Lymphoma

Bendamustine + Obinutuzumab Induction With Obinutuzumab Maintenance in Untreated Mantle Cell Lymphoma

Start date: October 19, 2017
Phase: Phase 2
Study type: Interventional

This is a phase II single-arm, open-label, multicenter study evaluating the efficacy and safety of the combination of induction chemoimmunotherapy with bendamustine and obinutuzumab (BO) followed by consolidation therapy and maintenance therapy with obinutuzumab in subjects who have not received prior cytotoxic chemotherapy for their MCL (i.e., prior single agent rituximab is permitted, prior involved-field radiotherapy is permitted).

NCT ID: NCT03272633 Terminated - Clinical trials for Acute Lymphoblastic Leukemia

Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies

Start date: October 26, 2020
Phase: Early Phase 1
Study type: Interventional

This pilot clinical trial studies the side effects of irradiated donor cells following stem cell transplant in controlling cancer in patients with hematologic malignancies. Transfusion of irradiated donor cells (immune cells) from relatives may cause the patient's cancer to decrease in size and may help control cancer in patients receiving a stem cell transplant.

NCT ID: NCT03229382 Terminated - Clinical trials for Mantle Cell Lymphoma

Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse

OPERA-PLRG10
Start date: May 14, 2018
Phase: Phase 2
Study type: Interventional

The objective of the study is the evaluation of efficacy and safety of obinutuzumab preemptive treatment at the time of the molecular relapse after first line immunochemotherapy with autologous stem cell transplantation in mantle cell lymphoma patients.

NCT ID: NCT03151057 Terminated - Clinical trials for Mantle Cell Lymphoma

Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignancies

Start date: July 31, 2018
Phase: Phase 1
Study type: Interventional

This is a study to evaluate the safety of idelalisib as post-transplantation maintenance in patients with B cell hematologic malignancies undergoing a allogeneic hematopoietic stem cell transplant (HSCT). Safety will be evaluated through the assessment of cytopenias, effect on donor chimerism, effect on the incidence and severity of acute graft versus host disease, and gastro-intestinal tolerance.

NCT ID: NCT03037645 Terminated - Clinical trials for Chronic Lymphocytic Leukemia

Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers

Start date: April 28, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label Phase 1b/2 study in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)or non hodgkin's lymphoma (NHL) who have failed prior standard of care therapies including a BTK inhibitor where one is approved for the indication.